Romiplostim or Standard of Care in Patients with Immune ThrombocytopeniaDavid J. Kuter, Dietmar Berger, Francesco Rodeghiero et al.|New England Journal of Medicine|2010Cited by 425
Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.David J. Kuter, Dietmar Berger, Mathias Rummel et al.|Blood|2009Cited by 7
The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.Ralph V. Boccia, Richard Lizambri, Xuena Wang et al.|Blood|2010Cited by 2